These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 812667)
21. A cooperative study on the clinical aspects of migraine and vascular headache and their response to sandomigran. Espadaler JM; Gimeno A; Lage AM Arch Neurobiol (Madr); 1974; 37 SUPPL():206-26. PubMed ID: 4462482 [No Abstract] [Full Text] [Related]
22. Experimental and clinical results with pizotifen in the treatment of underweight patients. Dolecek R Pharmatherapeutica; 1980; 2(6):363-71. PubMed ID: 7433478 [No Abstract] [Full Text] [Related]
23. Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. Gillies D; Sills M; Forsythe I Eur Neurol; 1986; 25(1):32-5. PubMed ID: 3510125 [TBL] [Abstract][Full Text] [Related]
24. [Comparative evaluation of the new antiserotonin preparations, sandomigran and lizenil, in treating patients suffering from migraine]. Matevosian AA Zh Eksp Klin Med; 1976; 16(5):95-100. PubMed ID: 799448 [No Abstract] [Full Text] [Related]
25. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Louis P; Spierings EL Cephalalgia; 1982 Dec; 2(4):197-203. PubMed ID: 6760980 [TBL] [Abstract][Full Text] [Related]
26. Long-term administration of pizotifen to migraine patients: effects on oral glucose tolerance tests and on insulin levels. Cerdan A; Acosta M; Jolin T; Spain M Headache; 1975 Jul; 15(2):126-8. PubMed ID: 1150429 [No Abstract] [Full Text] [Related]
27. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Osterman PO Acta Neurol Scand; 1977 Jul; 56(1):17-28. PubMed ID: 327746 [TBL] [Abstract][Full Text] [Related]
32. Flunarizine vs. pizotifen in migraine prophylaxis: a review of comparative studies. Spierings EL; Messinger HB Cephalalgia; 1988; 8 Suppl 8():27-30. PubMed ID: 3180199 [TBL] [Abstract][Full Text] [Related]
33. Fulminant hepatitis possibly related to pizotifen therapy. Elouni B; Ben Salem C; Zamy M; Poupon R; Bouraoui K; Biour M Ann Pharmacother; 2010; 44(7-8):1348-9. PubMed ID: 20571104 [No Abstract] [Full Text] [Related]
34. Platelet alpha-adrenergic receptor activity and pizotifen in migrainous children. Bond PA; Salmon MA Cephalalgia; 1985 Mar; 5(1):25-9. PubMed ID: 2985264 [TBL] [Abstract][Full Text] [Related]
35. The effect of an antiserotonin agent pizotifen on platelet aggregability in migraine patients. Mazal S; Rachmilewitz EA J Neurol Neurosurg Psychiatry; 1980 Dec; 43(12):1137-40. PubMed ID: 7217961 [TBL] [Abstract][Full Text] [Related]
36. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. Kangasniemi P Headache; 1979 May; 19(4):219-22. PubMed ID: 156165 [No Abstract] [Full Text] [Related]
37. Biochemical pharmacological profile of migraine prophylactics of pizotifen type. Dlohozková N; Metys J; Valchár M; Soucek R Act Nerv Super (Praha); 1989 Dec; 31(4):300-1. PubMed ID: 2638122 [No Abstract] [Full Text] [Related]
38. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Crowder D; Maclay WP Curr Med Res Opin; 1984; 9(4):280-5. PubMed ID: 6391831 [TBL] [Abstract][Full Text] [Related]
39. A retrospective study to assess the migraine headache remission rate after cessation of pizotifen therapy. Capildeo R; Wimalaratna HS; Bosley E; Shah SN Br J Clin Pract; 1990 Dec; 44(12):622-6. PubMed ID: 2102160 [No Abstract] [Full Text] [Related]
40. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Behan PO; Connelly K Headache; 1986 May; 26(5):237-9. PubMed ID: 3522482 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]